Medication | Dose | Route | Usual maximum daily dose | Potential adverse effects and target dose ranges |
Azithromycin |
| Oral |
|
|
Clarithromycin* |
| Oral |
|
|
Ethambutol* |
| Oral |
|
|
Rifabutin*¥ |
| Oral |
|
|
Rifampin (rifampicin)¥ |
| Oral |
|
|
Medications that may be added if Mycobacterium tuberculosis cannot be excluded | ||||
Isoniazid |
| Oral, IM |
|
|
Pyrazinamide* |
| Oral |
|
|
IM: intramuscular; IV: intravenous; MAC: Mycobacterium avium complex; NTM: nontuberculous mycobacterial infection (also known as atypical mycobacterial infection).
* Doses are for children with normal kidney function.
¶ Clinical data in adults indicate that 3 times weekly therapy is as effective as daily therapy, with reduced toxicity, for mild to moderate disease.
Δ Anterior uveitis, arthralgia, neutropenia, and liver function abnormalities may occur when clarithromycin is used in combination with rifabutin.
◊ Rare at doses of 15 to 25 mg/kg in children with normal kidney function.
§ Rarely occurs in children, who metabolize ethambutol more rapidly than adults.
¥ Dose may require modification based upon drug-drug interactions, particularly with clarithromycin.
‡ The incidence of hepatotoxicity may be increased when isoniazid doses >10 mg/kg are used in combination with rifampin.